BDO Life Sciences provided buy-side M&A, commercial due diligence and debt advisory services to Apiary Capital in connection with its significant investment in performance.io, the specialist provider of digital performance marketing services to the pharmaceutical industry.

Founded in 2017, performance.io is a specialist performance marketing agency focused on optimising the effectiveness of digital marketing for large pharmaceuticals companies, increasing organic online traffic to websites and content alongside improving patient and healthcare professional engagement. performance.io combines deep pharma expertise with best-in-class, tech-enabled SEO services, positioning performance.io as one of the few scaled specialists in the sector.

Apiary Capital is a UK-based private equity firm specialising in supporting owner-managed businesses. Apiary Capital's investment will support performance.io's management team, led by founder Matt Lowe, to accelerate its expansion in the US and Asia, as well as invest in people and technology.

 

“We really enjoyed working with the BDO Life Sciences Deals team on this transaction. Their understanding of the space and in-depth analytical review of performance.io's rapidly emerging market segment gave us invaluable insight into the opportunity, and their joined-up M&A, Commercial Due Diligence and Debt Advisory offering ensured efficient communication and collaboration throughout the process.

The whole team consistently went above and beyond to help us deliver the transaction, and we look forward to working with them in future.” 
Jessica French, Investment Director, Apiary Capital

The BDO project team included:
M&A: Alex Mackay, Calum McMillan, Zak Holdaway, Mohamed Khelloufi, James Fleming
CDD: David Wentholt, Sam Harraden, James Day, Sarah Postlethwaite, Charles Jervis
Debt Advisory: Steve Carr, Anish Mehta